期刊
CLINICAL BIOCHEMISTRY
卷 44, 期 10-11, 页码 853-858出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.clinbiochem.2011.04.001
关键词
Oxidative stress; Melatonin therapy; Muscular dystrophy; Erythrocytes
资金
- Instituto de Salud Carlos III [RD06/0013/0008, PI08-1644]
- Servicio Andaluz de Salud [422/2006]
- Consejeria de Innovacion, Ciencia y Empresa, Junta de Andalucia [P07-CTS-03135, CTS-190, CTS-101]
- Consejeria de Innovacion, Ciencia y Empresa (Junta de Andalucia, Spain)
Objectives: To analyze whether the antioxidant melatonin could reduce the hyperoxidative status in the blood of patients with Duchenne's muscular dystrophy. Design and methods: Ten patients aged 12.8 +/- 0.9 years were treated with melatonin (60 mg at 21:00 h plus 10 mg at 09:00 h) for 9 months, and erythrocyte markers of oxidative stress were determined at 3, 6, and 9 months of treatment. Healthy age- and sex-matched subjects served as controls. Results: Prior to treatment, the patients had higher glutathione disulfide/glutathione ratio and higher glutathione transferase and superoxide dismutase activities, and lower glutathione reductase activity than controls. After 3 months of melatonin treatment, the hyperoxidative status of these patients was counteracted, being reduced to the normal redox state between 3 and 9 months. Conclusion: These results, together with the reduction in the inflammatory process and in muscle injury recently reported in the same patients, support the efficacy of melatonin therapy in DMD patients. (C) 2011 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据